Sunday 18 October 2026
Export OBIO’s income statement to Excel — free account
Orchestra BioMed Holdings, Inc.
OBIO Healthcare Biotechnology
Orchestra BioMed Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.5 million, up 1,169.2% from fiscal 2024. In the quarter to June 2026, revenue fell 89.5%, EPS grew 24.0%, free cash flow fell 25.9% and total debt rose 142.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.45
0.29
−5.05%
Follow OBIO
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 10.49 | 9.68 | 9.78 | 4.26 | 3.96 | 2.20 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 13.00 | 14.66 | 10.15 | 23.39 | 10.06 | 6.30 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 4 | 4 | 4 | 56 | 70 | 86 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.88 | 0.05 | 0.04 | 0.39 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 4 | 3 | 3 | 33 | ||||
| Gross margin, % | — | — | — | — | — | — | 94.03 | 93.26 | 92.27 | 99.43 | |||||
| EBT | — | — | — | — | 0 | 0 | (34) | (49) | (61) | (53) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | (951.26) | (1,779.71) | (2,313.27) | (157.40) | |||||
| Net income | — | 0 | — | 0 | 0 | 0 | (34) | (49) | (61) | (53) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | 0 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.24 | 0.08 | 0.07 | 0.70 | ||||
| Earnings | — | — | — | — | (0.01) | (0.02) | (2.24) | (1.48) | (1.66) | (1.11) | |||||
| Cash flow | — | — | — | — | (0.02) | (0.01) | (1.95) | (1.39) | (1.37) | (1.03) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | (0.04) | 0.00 | (0.01) | (0.01) | |||||
| Free cash flow | — | — | — | — | (0.02) | (0.01) | (1.99) | (1.39) | (1.38) | (1.04) | |||||
| Book value | — | — | — | — | (0.23) | (0.19) | 3.50 | 2.05 | 0.90 | 1.12 | |||||
| Shares, m | — | — | — | — | 16 | 20 | 15 | 33 | 37 | 48 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | 42.60 | 105.69 | 55.83 | 5.92 | |||||
| P/B | — | — | — | — | — | — | 2.86 | 4.29 | 4.47 | 3.70 | |||||
| EV/Sales | — | — | — | — | — | — | 21.57 | 74.36 | 35.92 | 3.16 | |||||
| EV/FCF | — | — | — | — | — | — | (2.55) | (4.44) | (1.86) | (2.14) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | 0 | (29) | (46) | (51) | (49) | ||||
| Capex | — | — | — | — | — | — | (1) | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | 0 | 0 | (30) | (46) | (51) | (49) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 2 | 2 | 66 | 78 | 53 | 91 | ||||
| Total debt | — | — | — | — | — | — | 9 | — | 14 | 14 | |||||
| Net debt | — | — | — | — | (2) | (2) | (74) | (88) | (53) | (92) | |||||
| Shareholders’ equity | — | — | — | — | (4) | (4) | 53 | 68 | 33 | 54 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (0.21) | (0.23) | (26.11) | (51.49) | (71.21) | (55.44) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | 4.62 | 10.09 | (138.33) | (81.47) | (120.84) | (122.40) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Orchestra BioMed Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AVIR Atea Pharmaceuticals, Inc. | $363.3M | — (loss-making) | — (loss-making) | +295.16% (above 0%: growing) | n/m | +85.53% (above 0%: growing) | 0.00% | 0.00% | Compare |
| FENC Adherex Technologies Inc. | $362.9M | — (loss-making) | 31.4× | +85.18% (above 0%: growing) | n/m | +101.36% (above 0%: growing) | 95.97% | 9.72% | Compare |
| TTRX Turn Therapeutics Inc. | $345.3M | — (loss-making) | — | — | n/m | −74.76% (below 0%: shrinking) | — | 0.00% | Compare |
| OBIO Orchestra BioMed Holdings, Inc. | $345.0M | — (loss-making) | — (loss-making) | −89.47% (below 0%: shrinking) | n/m | −25.87% (below 0%: shrinking) | 71.59% | (25,404.55%) | |
| CCCC C4 Therapeutics, Inc. | $342.0M | — (loss-making) | — (loss-making) | +2.75% (above 0%: growing) | n/m | +86.84% (above 0%: growing) | 100.00% | (397.88%) | Compare |
| RLMD Relmada Therapeutics, Inc. | $341.3M | — (loss-making) | — | — | n/m | −50.06% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IRD Opus Genetics, Inc. | $336.9M | — (loss-making) | — (loss-making) | −73.80% (below 0%: shrinking) | n/m | −16.37% (below 0%: shrinking) | 100.00% | (2,182.78%) | Compare |
| ENTA Enanta Pharmaceuticals, Inc. | $334.1M | — (loss-making) | — (loss-making) | −21.60% (below 0%: shrinking) | n/m | −157.51% (below 0%: shrinking) | 100.00% | (120.04%) | Compare |
| CYPH Cypherpunk Technologies Inc. | $325.5M | 4.4× | — (loss-making) | 0.00% | n/m | +15.53% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $341.7M | — | — | +1.38% | — | −0.42% | 95.97% | 0.00% |
Orchestra BioMed Holdings, Inc. (OBIO) key facts
- Strength: Orchestra BioMed Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.5 million, up 1,169.2% from fiscal 2024.
- Orchestra BioMed Holdings, Inc. (OBIO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, OBIO traded at $5.45, a market capitalization of $345.0 million.
- Return on equity was −122.4% and debt-to-equity 1.80.
- Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −2.72 (distress zone) for fiscal 2025.